On April 11, 2005, the Food and Drug Administration issued a Public Health
	Advisory to inform healthcare professionals about a 1.6 to 1.7x  higher risk of
	mortality for elderly demented patients following exposure to the “2nd
	generation” antipsychotic drugs.  This alert reflected the detection of higher
	death rates – mostly cardiac or pulmonary – in the FDA’s “Randomized
	Controlled Trial” database for olanzapine (Zyprexa), risperidone (Rispderdal),
	and quetiapine (Seroquel).
	Two years later, this warning was revised and expanded because of further
	research discoveries.   On June 16, 2008, the FDA alerted physicians that the
	risk of premature death in elderly demented patients was elevated by both
	the “new” and “old” (1st generation) antipsychotic drugs.